pharma · Chronic Lymphocytic Leukaemia (CLL)
Servier Australia
Servier Laboratories (Aust.) Pty.
NovaPharmaNews editorial coverage mentioning Servier Australia — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 1954
- Employees
- 11
- Programs
- 1
- Drugs
- 7
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Servier Australia — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Servier Australia — regulatory, clinical, and market analysis.
Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Assets in Potential $2.7 Billion Deal
French pharmaceutical giant Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for an upfront payment of $1.55 billion, with potential milestone payments reaching up to $2.7 billion. This strategic move significantly expands Servier's footprint in the rare disease and neurology space.
GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition
GSK and Alfasigma have entered a licensing agreement for Linerixibat, while Servier has finalized a $2.5 billion acquisition of Day One Pharmaceuticals. This article explores the implications for the pharmaceutical landscape.